文献速递哮喘呼吸道感染

成人哮喘合并变应性支气管肺曲霉病的CT影像治疗反应评估

CT Imaging Assessment of Response to Treatment in Allergic Bronchopulmonary Aspergillosis in Adults With Bronchial Asthma.
PubMed 文献 · Chest · 2024-02-20

本研究为NebuLamB随机临床试验的辅助研究,纳入132例具有可用CT扫描且4个月急性期治疗期间无急性加重的哮喘合并变应性支气管肺曲霉病患者,分析治疗前后CT参数变化以评估影像学反应。结果发现黏液栓范围与密度、小叶中心微结节、实变/磨玻璃影及支气管壁增厚共5个CT参数在治疗末显著改善(P < .05),但影像学反应与临床及免疫学反应之间一致性差(Cohen κ,-0.01至0.24)。

要点

  • 黏液栓范围与密度、小叶中心微结节、实变/磨玻璃影及支气管壁增厚是评估影像学反应最相关的CT参数。
  • 影像学反应与临床、免疫学反应之间一致性差,应多维综合评估治疗结局。
  • 建议采用复合定义评估变应性支气管肺曲霉病的治疗反应。

核心结论

  • 黏液栓范围与密度、小叶中心微结节、实变/磨玻璃影及支气管壁增厚的改变是评估变应性支气管肺曲霉病影像学治疗反应最相关的CT参数。
  • 临床、免疫学与影像学反应之间无一致性,应采用多维复合定义评估治疗结局。

研究设计与样本

  • 本研究为随机临床试验NebuLamB的辅助研究,纳入132例具有可用CT扫描且4个月急性期治疗期间无急性加重的哮喘合并变应性支气管肺曲霉病患者。
  • 由两名对临床数据设盲的放射科医师在治疗开始与结束时系统分析CT扫描,筛选随时间显著变化的影像学参数。

主要发现

  • 治疗结束时5个CT参数显著改善:黏液栓范围、黏液栓密度、小叶中心微结节、实变/磨玻璃影及支气管壁增厚(P < .05)。
  • 除黏液栓范围与密度之间外,上述CT参数变化之间仅呈弱相关。
  • 临床、免疫学与影像学反应之间无一致性,总体反应或各参数单独分析时Cohen κ为-0.01至0.24。

关键数值与推荐

  • 影像学反应定义为至少一个CT参数改善且其他参数无恶化。
  • 共识别5个显著变化的CT参数:黏液栓范围、黏液栓密度、小叶中心微结节、实变/磨玻璃影及支气管壁增厚(P < .05)。
  • 影像学与临床及免疫学反应间Cohen κ为-0.01至0.24。

临床怎么用

  • 临床评估变应性支气管肺曲霉病治疗反应时应结合临床、免疫学及影像学多维指标,不应仅依赖单一维度。
  • 可重点随访黏液栓范围与密度、小叶中心微结节、实变/磨玻璃影及支气管壁增厚等CT参数变化。
  • 建议探索复合定义的治疗反应评估标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: One of the major challenges in managing allergic bronchopulmonary aspergillosis remains consistent and reproducible assessment of response to treatment. RESEARCH QUESTION: What are the most relevant changes in CT scan parameters over time for assessing response to treatment? STUDY DESIGN AND METHODS: In this ancillary study of a randomized clinical trial (NebuLamB), patients with asthma with available CT scan and without exacerbation during a 4-month allergic bronchopulmonary aspergillosis exacerbation treatment period (corticosteroids and itraconazole) were included. Changed CT scan parameters were assessed by systematic analyses of CT scan findings at initiation and end of treatment. CT scans were assessed by two radiologists anonymized to the clinical data. Radiologic parameters were determined by selecting those showing significant changes over time. Improvement of at least one, without worsening of the others, defined the radiologic response. Agreement between radiologic changes and clinical and immunologic responses was likewise investigated. RESULTS: Among the 139 originally randomized patients, 132 were included. We identified five CT scan parameters showing significant changes at end of treatment: mucoid impaction extent, mucoid impaction density, centrilobular micronodules, consolidation/ground-glass opacities, and bronchial wall thickening (P < .05). These changes were only weakly associated with one another, except for mucoid impaction extent and density. No agreement was observed between clinical, immunologic, and radiologic responses, assessed as an overall response, or considering each of the parameters (Cohen κ, -0.01 to 0.24). INTERPRETATION: Changes in extent and density of mucoid impaction, centrilobular micronodules, consolidation/ground-glass opacities, and thickening of the bronchial walls were found to be the most relevant CT scan parameters to assess radiologic response to treatment. A clinical, immunologic, and radiologic multidimensional approach should be adopted to assess outcomes, probably with a composite definition of response to treatment. TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT02273661; URL: www. CLINICALTRIALS: gov).

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Godet, Brun, Couturaud, et al. CT Imaging Assessment of Response to Treatment in Allergic Bronchopulmonary Aspergillosis in Adults With Bronchial Asthma. Chest. 2024. PMID: 38387646. doi:10.1016/j.chest.2024.02.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。